Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anastrozole and Palbociclib in HR+, HER2- Metastatic Breast Cancer
NCT02942355Phase 2Active, not recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Dec 2016
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of palbociclib, anastrozole in breast cancer, sponsored by Wake Forest University Health Sciences. Started Dec 2016; status: active, not recruiting.
02
Drugs
palbociclibanastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02942355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02942355.